PALO ALTO, Calif.--(BUSINESS WIRE)--Syapse Inc. is collaborating with the California Institute for Quantitative Biosciences (QB3) to offer the Syapse Discovery application to life science startup companies.
QB3, which hosts more than 40 companies in the QB3 Garage/Innovation Network, is a multicampus institute founded to promote bioscience innovation at the University of California and spur economic development in the life sciences sector. The institute has begun offering the Syapse Discovery application to entrepreneurs as part of its array of products and services known as the “QB3 Startup in a Box,” which aims to help launch companies more efficiently.
“Our goal is to give entrepreneurs the tools and partnerships they need to make starting a company the easiest part of their work,” said QB3 Associate Director Douglas Crawford, PhD. “That includes connecting entrepreneurs with other young companies such as Syapse that are developing ways to make the research process more efficient. This is startups helping startups.”
The first company in QB3’s network to use the software is CellSight Technologies, which is developing new ways to mark stem cells for use in stem-cell therapies. CellSight is using Syapse Discovery to capture, organize, and share scientific results to help make scientific decisions faster and easier, according to CellSight Chief Executive Officer Aruna Gambhir.
Syapse provides users with immediate access to key results in an intuitive manner, resulting in faster biology-driven decisions and implementation of research plans.
“We are excited by our partnership with QB3 and look forward to helping entrepreneurs launch successful biomedical companies, beginning with CellSight,” said Matthew Cooper, CSO of Syapse. “By using Syapse, biomedical companies can better understand their research results and accelerate their biomedical product development. There are tens of thousands of biomedical startups just like CellSight who could benefit from using Syapse.”
About Syapse
Syapse Inc. develops software applications to accelerate biology-based research and product development. Spun out of Stanford University and led by an experienced, multidisciplinary team of entrepreneurs, software developers, and scientists, Syapse's applications enable faster, more informed weight-of-evidence decisions using biological information. Built on top of our proprietary BioSemantic Platform, Syapse applications deliver value to organizations of all sizes, from the individual scientist and small academic laboratories, to emerging biotechnology companies, to large molecular diagnostics and pharmaceutical companies. For more information, please see www.Syapse.com.
About QB3
The California Institute for Quantitative Biosciences (QB3) was created in 2000 to fuel the California bioeconomy. QB3 is a consortium of more than 200 laboratories from the University of California campuses at Berkeley, Santa Cruz, and San Francisco. Armed with world-class researchers, state-of-the-art facilities and entrepreneurial resources, QB3 is a multi-disciplinary institute designed to accelerate discovery and innovation to benefit society.
QB3 fosters cross-campus and interdisciplinary collaborations within the University of California, and stimulates partnerships between QB3 researchers and private industry. To realize the potential of discoveries, QB3 provides proof-of-concept funding, start-up incubator space, and educational programs. This alliance allows scientists from academia and industry to address the unmet needs of society, setting the stage for fundamental discoveries to drive the technologies, products, and industries of the 21st century. For more information, please visit http://qb3.org/.
About CellSight Technologies
CellSight Technologies is a privately held biotechnology company based in San Francisco, California. CellSight is enabling cell and gene therapies in living subjects through the use of imaging technologies. We offer custom imaging research services as well as prepackaged molecular imaging kits targeted at companies with imaging expertise as well as academic institutions. We have formed partnerships with large pharmaceutical companies to incorporate imaging studies during cell therapy & drug development. The technology that forms the basis for the company was developed by Dr. Sanjiv Gambhir's group at the Molecular Imaging Program at Stanford and has been demonstrated in pre-clinical and clinical studies. For more information, please visit http://www.cellsighttech.com.
The information stated above was prepared by Syapse and reflects solely the opinion of the corporation. Nothing in this statement shall be construed to imply any support or endorsement of Syapse, or any of its products, by The Regents of the University of California, its officers, agents and employees.